Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid

International Journal of Hyperthermia

Volumn 17, Issue 6, 2001, Pages 508-519

  Murata, R ^a   Overgaard, J ^a   Horsman, M R ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

5,6 Dimethylxanthenone 4 acetic acid; C3H mouse mammary carcinoma; Hyperthermia; Normal tissue damage; Vascular targeting

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; RUBIDIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; BREAST CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG TARGETING; EXTRACTION; FEMALE; FOOT; HEATING; HIGH TEMPERATURE; HISTOPATHOLOGY; HYPERTHERMIC THERAPY; LOW TEMPERATURE; MOUSE; NECROSIS; NONHUMAN; PERFUSION; THERMAL EXPOSURE; THERMODYNAMICS; TISSUE INJURY; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HYPERTHERMIA, INDUCED; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; NECROSIS; REGIONAL BLOOD FLOW; TUMOR NECROSIS FACTOR-ALPHA; XANTHENES; XANTHONES;

EID: 0035158004     PISSN: 02656736     EISSN: None     Source Type: Journal    
DOI: 10.1080/02656730110087040     Document Type: Article

References (40)

1. Vascular attack as a therapeutic strategy for cancer
2. Tumour vasculature as a target for cancer therapy
3. Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours
4. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid
5. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid
6. Enhancement of the antitumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs
7. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
8. Stimulation of tumors to synthesize tumor necrosis factor-α in situ using 5,6-dimethylxanthenone-4-acetic acid: A novel approach to cancer therapy
9. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues
10. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids
11. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown
12. Induction of tumor necrosis factor-α messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488)
13. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma
14. Reduction of tumor blood flow by flavone acetic acid: A possible component of therapy
15. Vascular collapse after flavone acetic acid: A possible mechanism of its anti-tumour action
16. The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels
17. The in vivo interaction between flavone acetic acid and hyperthermia
18. Flavone acetic acid directly induces expression of cytokine genes in mouse splenic leukocytes but not in human peripheral blood leukocytes
19. Production of tumour necrosis factor-α by cultured human peripheral blood leucocytes in response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488)
20. The effects of heat and radiation on cancers implanted on the feet of mice
21. The effect of vascular occlusion on the thermal sensitization of a mouse tumour
22. Cell kill and tumor control after heat treatment with and without vascular occlusion in RIF-1 tumors
23. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo
24. Substantial enhancement of tumor hyperthermic response by tumor necrosis factor
25. Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSaII tumors
26. A study of the mechanism of hydralazine enhancement of thermal damage in the KHT tumour
27. Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs
28. The use of hydralazine to manipulate tumour temperatures during hyperthermia
29. The role of tissue environmental factors on the kinetics and morphology of tumor cells exposed to hyperthermia
30. The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro
31. Response of cells to hyperthermia under acute and chronic hypoxic conditions
32. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation
33. Hyperthermia from the clinic to the laboratory: A hypothesis
34. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo
35. Regional blood flow by fractional distribution of indicators
36. The interaction between RSU-1069, hydralazine and hyperthermia in a C3H mammary carcinoma as assessed by tumour growth delay
37. The influence of tumour temperature on ischemia-induced cell death: Potential implications for the evaluation of vascular mediated therapies
38. Ischaemia induced cell death in tumors: Importance of temperature and pH
39. Hyperthermia-induced changes in the vascularity and histopathology of a murine tumour and its surrounding normal tissue
40. Hyperthermic treatment of malignant diseases: Current status and a view toward the future